Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Kalle Sigfridsson"'
Autor:
Krishna C. Aluri, Kalle Sigfridsson, Aixiang Xue, Niresh Hariparsad, Dermot McGinnity, Diane Ramsden
Publikováno v:
International Journal of Pharmaceutics. 636:122787
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d0160602a55583fed8be67cfca52654
https://doi.org/10.1016/j.ijpharm.2023.122787
https://doi.org/10.1016/j.ijpharm.2023.122787
Publikováno v:
European Journal of Pharmaceutical Sciences. 128:128-136
AZ3411 was selected as a lead compound for the treatment of Inflammatory Bowel Disease (IBD). The present research aimed to perform an early pharmaceutical assessment of this NK antagonist candidate focusing on the challenging solid-state part of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed176da69c860aa762be46196f40d5ef
https://doi.org/10.1016/j.ejps.2018.11.028
https://doi.org/10.1016/j.ejps.2018.11.028
Autor:
Sofia Martinsson, Christopher J.H. Porter, Erik Michaëlsson, Kalle Sigfridsson, Anna Lindgren, Lennart Lindfors, Enyuan Cao, Luojuan Hu, Natalie L. Trevaskis, Urban Skantze
Publikováno v:
Journal of Controlled Release. 296:29-39
Lymphocytes play a central role in the pathology of a range of chronic conditions such as autoimmune disease, transplant rejection, leukemia, lymphoma HIV/AIDs and cardiometabolic diseases such as atherosclerosis. Current treatments for lymphocyte-as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c90fdff52ba3dfcffd66779196b8dfb
https://doi.org/10.1016/j.jconrel.2019.01.002
https://doi.org/10.1016/j.jconrel.2019.01.002
Autor:
Aixiang Xue, Torbjörn Arvidsson, David J. Wagner, Kalle Sigfridsson, Guangnong Zhang, Marie Strimfors, Petar Pop-Damkov
Publikováno v:
International journal of pharmaceutics. 581
The aim of the present study was to evaluate and interpret the pharmacokinetic profiles after subcutaneous (s.c.) administration of crystalline AZ’72 nano- and microsuspensions to rodents. Both formulations were injected at 1.5 and 150 mg/kg to rat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32dd20578d58fb4ed419c320b64607cd
https://pubmed.ncbi.nlm.nih.gov/32240808
https://pubmed.ncbi.nlm.nih.gov/32240808
Publikováno v:
International Journal of Pharmaceutics. 606:120883
In the present study we describe a way of working to overcome oral administration challenges in an early preclinical project. As candidate drugs were obtained, the preclinical delivery route was replaced by the intended route of the product and resou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e77b88c42515d97bbd2b8bb718a9a3a5
https://doi.org/10.1016/j.ijpharm.2021.120883
https://doi.org/10.1016/j.ijpharm.2021.120883
Autor:
Kalle Sigfridsson, Karin E. Carlsson
Publikováno v:
European Journal of Pharmaceutical Sciences. 109:650-656
A candidate drug within the cardiovascular area was identified during early research and evaluated for further development. The aim was to understand and explain the degradation mechanisms for the present compound. The stability of the active pharmac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1748fa530ff6aaeda83f1ef898724bc5
https://doi.org/10.1016/j.ejps.2017.07.018
https://doi.org/10.1016/j.ejps.2017.07.018
Publikováno v:
European Journal of Pharmaceutical Sciences. 104:262-272
A compound, which is a selective peroxisome proliferator activated receptor (PPAR) agonist, was investigated. The aim of the presented studies was to evaluate the potential of the further development of the compound. Fundamental physicochemical prope
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27a410a389535d15dac7fb743aa89d41
https://doi.org/10.1016/j.ejps.2017.03.041
https://doi.org/10.1016/j.ejps.2017.03.041
Autor:
Kjetil Elvevold, Bård Smedsrød, Erik Michaëlsson, Lena Svensson, Lars Löfgren, Lennart Lindfors, Pär Nordell, Kalle Sigfridsson, Britt Fuglesteg, Urban Skantze, Pia Skantze
Publikováno v:
International Journal of Pharmaceutics. 524:248-256
A stabilized high drug load intravenous formulation could allow compounds with less optimal pharmacokinetic profiles to be developed. Polyethylene glycol (PEG)-ylation is a frequently used strategy for particle delivery systems to avoid the liver, th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52c70099aaf49af78bab667f236eb5cd
https://doi.org/10.1016/j.ijpharm.2017.03.062
https://doi.org/10.1016/j.ijpharm.2017.03.062
Autor:
Svante Johansson, Bård Smedsrød, Urban Skantze, Lennart Lindfors, Pia Skantze, Kjetil Elvevold, Britt Fuglesteg, Iain Grant, Kalle Sigfridsson
Publikováno v:
International Journal of Pharmaceutics. 518:29-40
In the present work, milled nanocrystals of a poorly soluble compound using different stabilizers were prepared and characterized. The aim of the study was to evaluate a fundamental set of properties of the formulations prior to i.v. injection of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a04334b6d043fa74e0445f51f9f63403
https://doi.org/10.1016/j.ijpharm.2016.12.035
https://doi.org/10.1016/j.ijpharm.2016.12.035
Publikováno v:
International journal of pharmaceutics. 566
The objective of the study was to evaluate the pharmacokinetic profile after different subcutaneous (s.c.) administrations of nano- and microparticle suspensions of griseofulvin to mice. The solubility of the compound was determined as approximately
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7faf4fd481e7fcfdf8b97413f060e2c0
https://pubmed.ncbi.nlm.nih.gov/31181305
https://pubmed.ncbi.nlm.nih.gov/31181305